189 related articles for article (PubMed ID: 33418504)
1. How to select cancer patients for immunotherapy.
Pfeiffer P; Qvortrup C; Hansen KH
EBioMedicine; 2021 Jan; 63():103184. PubMed ID: 33418504
[No Abstract] [Full Text] [Related]
2. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
Raibagkar P
Immunol Lett; 2020 May; 221():72-74. PubMed ID: 32092358
[No Abstract] [Full Text] [Related]
3. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Zou Y; Hu X; Zheng S; Yang A; Li X; Tang H; Kong Y; Xie X
EBioMedicine; 2021 Jan; 63():103137. PubMed ID: 33310681
[TBL] [Abstract][Full Text] [Related]
4. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
Xu Y; Fu Y; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():2023. PubMed ID: 33123120
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
Galluzzi L; Humeau J; Buqué A; Zitvogel L; Kroemer G
Nat Rev Clin Oncol; 2020 Dec; 17(12):725-741. PubMed ID: 32760014
[TBL] [Abstract][Full Text] [Related]
6. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
Agur Z; Elishmereni M; Foryś U; Kogan Y
Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891
[TBL] [Abstract][Full Text] [Related]
7. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?
Sobhani N; Corona SP; Roviello G; Bagby S; D'Angelo A; Iezzi G; Generali D
Future Oncol; 2020 Jul; 16(19):1327-1330. PubMed ID: 32396404
[No Abstract] [Full Text] [Related]
8. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.
Zhang PF; Xie D; Li Q
Future Oncol; 2020 Jun; 16(17):1189-1198. PubMed ID: 32407173
[No Abstract] [Full Text] [Related]
10. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.
Duchemann B; Pluvy J; Crestani B; Zalcman G; Nunes H
Eur J Cancer; 2021 Mar; 145():179-182. PubMed ID: 33486441
[No Abstract] [Full Text] [Related]
11. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
Barroso-Sousa R; Tolaney SM
Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors - The Need for Innovation.
Johnson PC; Gainor JF; Sullivan RJ; Longo DL; Chabner B
N Engl J Med; 2023 Apr; 388(16):1529-1532. PubMed ID: 37075146
[No Abstract] [Full Text] [Related]
13. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P; Singh PK; Malik PS; Singh N
Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
[TBL] [Abstract][Full Text] [Related]
14. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
15. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
Yao S; Li X; Nong J; Zhang Y
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
[TBL] [Abstract][Full Text] [Related]
16. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
Reich M; Coutzac C
Bull Cancer; 2021 Mar; 108(3):228-229. PubMed ID: 33531154
[No Abstract] [Full Text] [Related]
17. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
18. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
Fazio N; Abdel-Rahman O
Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
[TBL] [Abstract][Full Text] [Related]
19. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Fernandes S; Varlamov EV; McCartney S; Fleseriu M
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 Nov; 15(31):3633-3646. PubMed ID: 31650854
[No Abstract] [Full Text] [Related]
[Next] [New Search]